Shandong International Biotechnology Park (the Park) is jointly built by Yantai High-tech Zone and Luye Investment Group Ltd. with the support from Department of Science and Technology of Shandong Province and Yantai Municiple Government. The Park adopts innovative mode of “enterprise-style management with strong governmental support”, which is a new attempt in building innovative system.
Located in the core area of Yantai High-tech Zone, composed of R&D section and the living section, the Park covers an area of 1,046 mu and the gross floor area is 1,070,000 ㎡, 560,000 ㎡ of which is R&D section. Advocating the concept of healthy living technologies, the Park will establish the most optimum research environment and living conditions in international standards, and provide full services such as technologies, funds and the living conditions for the enterprises and organizations settled in the Park. The Park will make efforts towards the target of building a world-class biotechnology base.
The Park has taken the strategic opportunities in building the Shandong Peninsula Blue Economic Zone and developing the biotechnology industry. In 2010, the Park has been selected in the “6 top 10” scientific and technological innovation project of Yantai City, and become one of the major ten parks that will be highly supported by the government in the next five years. The Park has become one of the major three “National Drug Innovation Incubator Base” of Shandong province, and the important part of “Shandong National New Drug R&D Technology Platform” and “Shandong New Drug Innovation and development center”. May 2011, the Park was selected in the first 100 strategic new emerging industrial projects of Shandong province which will get government support in terms of finance, credit, land use, etc. The Park won the Innovation Prize in the fifth China Independent Innovation Appraisal Activity. At present, the Park has taken part in 6 technological projects of city level or national level and gained the financial support of more than 10 million RMB.
In terms of the development strategy, the Park will be specialized in the high-end industries like biopharmaceutical, marine biopharmaceutical, biological agriculture, etc. aiming at “first-class in China and advanced in the world, with centralized advantages and prominent features”; and promote the construction of modern biopharmaceutical industry system centered on the R&D and innovation, pilot test incubation, and matching services. The Park has also established Drug Safety Evaluation Center, Biotechnology Center, Analysis & Test Center, Drug Screening & Evaluation Center, and Pharmacokinetics Research Center, Marine Bio-pharmacy R&D Center, Pilot Test Base, etc.
Since the inception of the project, it has gained positive responses from the industry both home and abroad. At present, more than 10 famous research institutes and universities have signed the admission contracts with the Park, including Institute of Shanghai Institute of Materia Medica, Tongji University, China Pharmaceutical University, Chinese Academy of Sciences; National Center for Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences; Singapore JURONG International Holdings Pte Ltd.; Modern Research Center of Traditional Chinese Medicine, Tsinghua University; Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences; Bio-resource Laboratory, Institute of Coastal Zone Research, Chinese Academy of Sciences; Tianjin Institute of Pharmaceutical Research; America Hamner Institutes for Health Sciences; Institute of Marine Biology, Far East Branch, Russian Academy of Sciences; Beijing Vigoo Biological Co Ltd. (New Vaccine National Engineering Research Center); Tongji University, Shandong University, Shanghai University of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Fudan University, Zhejiang University, as well as Venture Capitalists like Softbank China Venture Capital(SBCVC) and America Trout Capital Group LLC.
At present, more than 20 biotechnology innovation projects have signed contracts with the Park and moved in the Park. The projects cover various biology and pharmaceutical technologies like therapeutic protein, polypeptide, monoclonal antibody, stem cells, bio diagnostic reagent, biological diagnostic reagent, biochip, biosimilar drug, marine pharmaceutical, modern Chinese medicine, medical equipment, animal vaccines and drugs, bio-breeding, etc. And the project leaders and the talents mostly have overseas education background. The introduction of the projects and the talents will greatly promote the development of the Park.